Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1981 2
2002 1
2008 2
2010 4
2011 2
2012 3
2013 1
2015 1
2017 1
2018 3
2019 6
2020 1
2021 1
2022 4
2023 1
2024 3
2025 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

33 results

Results by year

Filters applied: . Clear all
Page 1
Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial.
Gerstein HC, Colhoun HM, Dagenais GR, Diaz R, Lakshmanan M, Pais P, Probstfield J, Riesmeyer JS, Riddle MC, Rydén L, Xavier D, Atisso CM, Dyal L, Hall S, Rao-Melacini P, Wong G, Avezum A, Basile J, Chung N, Conget I, Cushman WC, Franek E, Hancu N, Hanefeld M, Holt S, Jansky P, Keltai M, Lanas F, Leiter LA, Lopez-Jaramillo P, Cardona Munoz EG, Pirags V, Pogosova N, Raubenheimer PJ, Shaw JE, Sheu WH, Temelkova-Kurktschiev T; REWIND Investigators. Gerstein HC, et al. Lancet. 2019 Jul 13;394(10193):121-130. doi: 10.1016/S0140-6736(19)31149-3. Epub 2019 Jun 9. Lancet. 2019. PMID: 31189511 Clinical Trial.
Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein.
Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, Kastelein JJ, Koenig W, Libby P, Lorenzatti AJ, MacFadyen JG, Nordestgaard BG, Shepherd J, Willerson JT, Glynn RJ; JUPITER Study Group. Ridker PM, et al. N Engl J Med. 2008 Nov 20;359(21):2195-207. doi: 10.1056/NEJMoa0807646. Epub 2008 Nov 9. N Engl J Med. 2008. PMID: 18997196 Free article. Clinical Trial.
Triglyceride Lowering with Pemafibrate to Reduce Cardiovascular Risk.
Das Pradhan A, Glynn RJ, Fruchart JC, MacFadyen JG, Zaharris ES, Everett BM, Campbell SE, Oshima R, Amarenco P, Blom DJ, Brinton EA, Eckel RH, Elam MB, Felicio JS, Ginsberg HN, Goudev A, Ishibashi S, Joseph J, Kodama T, Koenig W, Leiter LA, Lorenzatti AJ, Mankovsky B, Marx N, Nordestgaard BG, Páll D, Ray KK, Santos RD, Soran H, Susekov A, Tendera M, Yokote K, Paynter NP, Buring JE, Libby P, Ridker PM; PROMINENT Investigators. Das Pradhan A, et al. N Engl J Med. 2022 Nov 24;387(21):1923-1934. doi: 10.1056/NEJMoa2210645. Epub 2022 Nov 5. N Engl J Med. 2022. PMID: 36342113 Clinical Trial.
Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial.
Gerstein HC, Colhoun HM, Dagenais GR, Diaz R, Lakshmanan M, Pais P, Probstfield J, Botros FT, Riddle MC, Rydén L, Xavier D, Atisso CM, Dyal L, Hall S, Rao-Melacini P, Wong G, Avezum A, Basile J, Chung N, Conget I, Cushman WC, Franek E, Hancu N, Hanefeld M, Holt S, Jansky P, Keltai M, Lanas F, Leiter LA, Lopez-Jaramillo P, Cardona Munoz EG, Pirags V, Pogosova N, Raubenheimer PJ, Shaw JE, Sheu WH, Temelkova-Kurktschiev T; REWIND Investigators. Gerstein HC, et al. Lancet. 2019 Jul 13;394(10193):131-138. doi: 10.1016/S0140-6736(19)31150-X. Epub 2019 Jun 9. Lancet. 2019. PMID: 31189509 Clinical Trial.
Protecting stable biological nomenclatural systems enables universal communication: A collective international appeal.
Jiménez-Mejías P, Manzano S, Gowda V, Krell FT, Lin MY, Martín-Bravo S, Martín-Torrijos L, Nieto Feliner G, Mosyakin SL, Naczi RFC, Acedo C, Álvarez I, Crisci JV, Luceño Garcés M, Manning J, Moreno Saiz JC, Muasya AM, Riina R, Meseguer AS, Sánchez-Mata D; 1543 additional coauthors. Jiménez-Mejías P, et al. Bioscience. 2024 Jun 19;74(7):467-472. doi: 10.1093/biosci/biae043. eCollection 2024 Jul. Bioscience. 2024. PMID: 39156614 Free PMC article.
N,N-Bis(diphenyl-phosphanyl)cyclo-propyl-amine.
Engelbrecht I, Visser HG, Roodt A. Engelbrecht I, et al. Acta Crystallogr Sect E Struct Rep Online. 2010 Oct 23;66(Pt 11):o2881. doi: 10.1107/S1600536810041711. Acta Crystallogr Sect E Struct Rep Online. 2010. PMID: 21589062 Free PMC article.
Cardiovascular Efficacy and Safety of Bococizumab in High-Risk Patients.
Ridker PM, Revkin J, Amarenco P, Brunell R, Curto M, Civeira F, Flather M, Glynn RJ, Gregoire J, Jukema JW, Karpov Y, Kastelein JJP, Koenig W, Lorenzatti A, Manga P, Masiukiewicz U, Miller M, Mosterd A, Murin J, Nicolau JC, Nissen S, Ponikowski P, Santos RD, Schwartz PF, Soran H, White H, Wright RS, Vrablik M, Yunis C, Shear CL, Tardif JC; SPIRE Cardiovascular Outcome Investigators. Ridker PM, et al. N Engl J Med. 2017 Apr 20;376(16):1527-1539. doi: 10.1056/NEJMoa1701488. Epub 2017 Mar 17. N Engl J Med. 2017. PMID: 28304242 Free article. Clinical Trial.
N,N-Bis(diphenyl-phosphan-yl)cyclo-butanamine.
Engelbrecht I, Visser HG, Roodt A. Engelbrecht I, et al. Acta Crystallogr Sect E Struct Rep Online. 2011 Aug 1;67(Pt 8):o2041-2. doi: 10.1107/S1600536811027656. Epub 2011 Jul 16. Acta Crystallogr Sect E Struct Rep Online. 2011. PMID: 22091069 Free PMC article.
N,N-Bis(diphenyl-phosphan-yl)cyclo--penta-namine.
Engelbrecht I, Visser HG, Roodt A. Engelbrecht I, et al. Acta Crystallogr Sect E Struct Rep Online. 2010 Nov 27;66(Pt 12):o3322-3. doi: 10.1107/S1600536810048907. Acta Crystallogr Sect E Struct Rep Online. 2010. PMID: 21589599 Free PMC article.
33 results